

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

GENOME THERAPEUTICS CORP

Form 8-K

July 09, 2001

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 8-K

CURRENT REPORT

Pursuant to

Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): July 9, 2001

-----  
GENOME THERAPEUTICS CORP.  
(Exact name of registrant as specified in its charter)

MASSACHUSETTS	0-10824	04-2297484
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

100 BEAVER STREET  
WALTHAM, MASSACHUSETTS 02453

(Address, of principal executive offices, including zip code)

(781) 398-2300

(Registrant's Telephone number including area code)

-----  
Page 1 of 4 pages.

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

Item 5. OTHER EVENTS

On July 9, 2001, Genome Therapeutics Corp. issued a press release announcing the financial results for the third quarter of its fiscal year 2001.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By /s/ Stephen Cohen

-----  
Name: Stephen Cohen  
Title: Chief Financial Officer

Date: July 9, 2001

EXHIBIT INDEX

99.1 Press Release dated July 9, 2001